BSX Options Flare Up as CEO's August Buy Sits 10% Underwater

The single most telling number on Boston Scientific this week is not the short interest, which at 2.7% of float remains unremarkable. It is the put/call ratio, which jumped to 0.63 on November 3, more than 3.6 standard deviations above its 20-day mean of 0.44. That is the loudest defensive signal the options market has sent on this name in the past year.

Options positioning turned sharply more cautious in one session, in a stock that had already fallen 3.5% on the week to $43.50. The PCR had been running in a narrow band around 0.41 to 0.47 for most of October. The sudden spike to 0.63 on November 3 stands out against that baseline. The 52-week high on the ratio is 1.10, so this is not an extreme in absolute terms, but the speed of the move is. Meanwhile the borrow market tells a different story: availability is effectively uncapped, with far more shares available to lend than are currently borrowed, and cost to borrow has risen sharply from 0.19% at end-October to 0.74% now, still a low absolute rate but the fastest three-week move in the data window. Shorts are not piling in; someone is buying protection.

The sell-side reset that followed the October 28 earnings print has already been covered in detail in earlier notes, but the picture since then has not improved. Ten firms lowered targets in two days. TD Cowen and Jefferies cut to Hold. The consensus mean target is $49.60, against a price of $43.50, which implies about 14% upside on paper. But that mean is itself the product of a mass downward revision: Jefferies moved from $60 to $46, UBS from $67 to $57, RBC from $70 to $52. Firms that kept positive ratings, including Bernstein, Leerink and Canaccord, all slashed their numbers. The bull case centres on AFib market expansion toward $15 billion by 2028 and volume growth in ablation procedures following recent trial results. The bear case is more immediate: RF procedure share is projected to slide from 34% to 23% by 2030, cryoablation share from 25% to 20%, and the company enters this cycle with heightened debt and limited operating leverage.

The peer comparison reinforces BSX's relative weakness. PEN, its highest-correlated peer and the target of a Boston Scientific acquisition agreed this year, fell just 1.2% on the week. ISRG and GMED each lost around 1% to 1.6%. MMSI dropped 10%, so BSX is not alone in having a difficult week in medtech, but its 3.5% decline puts it firmly in the weaker half of the peer group. MDT was the exception, gaining 5.2% over the same period.

The insider picture is now almost three months old but still defines the valuation debate. CEO Michael Mahoney's open-market purchase of 186,240 shares at $48.33, made without a 10b5-1 plan, was joined by two directors and the CFO across August, bringing 90-day net buying to roughly $9.3 million across about 192,000 net shares. The stock has not been back to those levels since. At $43.50, every insider who bought in August is sitting on a loss of between 7% and 15%. That gap between insider entry and current price is the clearest way to frame what the market has assigned as the Q3 discount. Alt data adds one note: ORTEX records Q3 2026 as the smallest quarter for share repurchases since 2011, with zero shares bought back. At a moment when the balance sheet is under scrutiny and insiders were buying with their own money, the absence of corporate buybacks is a data point worth holding alongside the rest.

ORTEX forecasts an 85% probability of a share-count increase in the CRSP US Mid index at the December 2026 Quarterly Review, with an estimated $613 million in buying from trackers around December 22. The same review carries an 85% probability of deletion from the CRSP US Mega index, a consequence of the share price decline compressing market cap to $63 billion, now 16.8% below the $73.6 billion cap that would put it back at the exit line ($50.79). Separately, the agreed acquisition of Penumbra drives ORTEX's 80% probability of an S&P 500 share-count adjustment, with an estimated $378 million in tracker buying around December 15 (dates are estimated pending index-provider confirmation). These are mechanical flows, not votes on the business, but the December rank date of December 4 for the CRSP review gives a specific event to monitor.

The CRSP rank date on December 4 and any formal S&P announcement around December 8 are the next concrete markers: watch whether the share price closes the gap to $50.79 before then, and whether options positioning normalises or extends its move to the defensive side of the range.